BUSINESS
Daiichi Sankyo’s ADC U3-1402 Shows Tumor Reduction in NSCLC Patients: Preliminary PI Data
Daiichi Sankyo has presented preliminary data from a PI study of its HER3 targeting antibody drug conjugate (ADC) U3-1402 in non-small cell lung cancer (NSCLC) patients, showing a reduction in tumor size in all evaluable patients. The study enrolled 23…
To read the full story
Related Article
- Daiichi Sankyo Presents Updated PI Data of ADCs DS-1062, U3-1402 for NSCLC
September 11, 2019
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





